John Wityak
CHDI Foundation(US)
Publications by Year
Research Areas
Genetic Neurodegenerative Diseases, Melanoma and MAPK Pathways, Platelet Disorders and Treatments, Monoclonal and Polyclonal Antibodies Research, Antiplatelet Therapy and Cardiovascular Diseases
Most-Cited Works
- → Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays(2004)1,285 cited
- → MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization products(1998)404 cited
- → 2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure−Activity Relationship Studies toward the Discovery of N -(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan -Src Kinase Inhibitor(2006)395 cited
- → Selective Itk Inhibitors Block T-Cell Activation and Murine Lung Inflammation(2004)112 cited
- → Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56lck inhibitors(2003)106 cited
- → Synthesis of 1,3-Diynes Using Palladium-Copper Catalysis(1991)89 cited
- → A Monoclonal Antibody TrkB Receptor Agonist as a Potential Therapeutic for Huntington’s Disease(2014)88 cited
- → Isoxazolines as Potent Antagonists of the Integrin αvβ3(1999)85 cited
- → Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors(2006)75 cited
- → Synthesis of Thrombin Inhibitor DuP 714(1995)75 cited